Friday, 19 Jan 2018

You are here

Guselkumab for Active Psoriatic Arthritis

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab (GUS), in patients with active psoriatic arthritis (PsA).  

Patients with active PsA and ≥3% body surface area of plaque psoriasis, both bio-naive and TNF experienced, were randomized 2:1 to receive GUS 100 mg subcutaneously (SC) or placebo (PBO) as follows:

 

  

Significant amount of patients in the treatment group achieved ACR 20 as early as week 4 (21% vs 0, p<0.001) and primary endpoint of ACR 20 response at wk24 was met in 58% of GUS patients RA as opposed to 18.4% in placebo group. Major secondary endpoints were PASI 75 and ACR 50 responses, change from baseline in HAQ-DI, and improvement in enthesitis (Leeds enthesitis index) and dactylitis score (by a 0–3 scoring system) at wk24 and were all significantly better in GUS group.

 

 

 

One patient in GUS groups developed grade 3 neutropenia that resolved after discontinuation of treatment. Infections were the most common AEs (PBO: 20.4%; GUS: 17.0%, respectively).

 

Overall, study concluded GUS demonstrated significant improvement of arthritis, psoriasis, enthesitis, dactylitis and quality of life and was well tolerated with no unexpected safety signals.

Add new comment

More Like This

The RheumNow Week in Review - 19 January 2018

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the rising cost of adalimumab, infections in myositis, phyisician burnout, biologics in Still's disease and weight loss benefits in RA. 

Rheumatology Physician Burnout and Depression

The 2018 Medscape Physician Burnout and Depression report shows that 42% of physician respondents report "burnout" and up to 15% experience some sort of depression. In a survey of 15,543 doctors from 29 specialties, they found highest burnout rates in critical care and neurologists (48%), family medicine (47%), ob/gyns and internists (46%). Lowest rates were seen in pathology and dermatology (32%), and plastic surgery (23%). 

What did rheumatologists report?

The RheumNow Week in Review - 12 January 2018

Dr. Jack Cush reviews a dozen highlights from the past week on RheumNow.com.

40% of Arthritis Patients Fail to Receive Exercise Guidance

The latest issue of CDC’s MMWR reports that exercise counseling among arthritis patients increased from 52% to 61% (2002 to 2014); hence ~40% do not receive health care provider counseling, suggesting the need for provider education and training in exercise counseling, and improved electronic medical record reminders.

The RheumNow Week in Review - 5 January 2018

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.